ClinicalTrials.gg
TerminatedNCT02367352Updated Jun 26, 2019Results posted

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

A Phase 1 interventional study of Alisertib and Paclitaxel in Advanced Solid Tumors, Ovarian Cancer and Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Ovarian Neoplasms by Takeda — none open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Takeda.

Started
2015
with 1 other
Phase 1
2 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Ovarian Neoplasms by Takeda, this one is one of 2 that started in 2015, is one of 2 in phase 1, and was the 5th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 11 studies in Ovarian Neoplasms by Takeda is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Ovarian Neoplasms by Takeda as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.

Read the detailed description

The drug being tested in this study was called alisertib. Alisertib in combination with paclitaxel was tested to find a safe and well-tolerated dose in East Asian participants. The study consisted of 2 parts: a dose escalation phase to determine the maximum tolerated dose (MTD) and define the recommended phase 2 dose (RP2D) of the alisertib plus paclitaxel combination in East Asian participants with advanced solid tumors; the second part is an expansion cohort at the RP2D of the alisertib plus paclitaxel in East Asian participants with either ovarian cancer or small cell lung cancer. This study looked at safety (lab results and side effects) and pharmacokinetic properties (how the drugs move throughout the body).

This open label study enrolled 9 participants. Dose Escalation Phase: Alisertib tablets at a starting dose of 15 mg, orally, twice daily, 3 days on/4 days off for 3 weeks in 28 day cycle in combination with paclitaxel, 60 mg/m\^2 intravenous on days 1, 8, and 15 in 28-day cycles in Cohort 1 escalated to a dose of 25 mg alisertib, orally, twice daily 3 days on/4 days off for 3 weeks in 28 day cycles in Cohort 2. If ≥ 2 participants experience a dose limiting toxicity (DLT) the dose of alisertib decreased to 20 mg. Expansion Cohort: alisertib tablets at the determined RP2D dose orally, twice daily 3 days on/4 days off for 3 weeks in 28 day cycles in combination with paclitaxel, 60 mg/m\^2 intravenous. Treatment was continued until disease progression or unacceptable toxicity.

  • Alisertib 15 mg to 25 mg tablets
  • Paclitaxel 60 mg/m\^2 intravenous solution

This multi-centre trial was conducted in Japan and Korea. The overall time to participate in this study was up to 24 months.

The study was terminated early because of the sponsor's decision. Enrollment was completed in the dose escalation cohort, but no participants were enrolled in the dose expansion cohort.

03

Conditions studied

  • Advanced Solid Tumors
  • Ovarian Cancer
  • Small Cell Lung Cancer

Keywords

  • Drug therapy
  • Dose escalation
  • Dose expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 18 years or older (or minimum age of legal consent consistent with local regulations) at the time written study is obtained.
  2. Participants of East Asian ethnicity (eg, Chinese, Japanese, or Korean).
  3. Must have a diagnosis of a solid tumor (escalation part) or ovarian cancer (OC) or small cell lung cancer (SCLC) (expansion part).

    • Participants in the expansion cohort must have a pathologically (histology or cytology) confirmed diagnosis of either OC (including recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer) or SCLC, which is as per (RECIST), version 1.1.
    • Participants in the expansion cohort must not have received more than 2 prior taxane containing regimens.
  4. No antineoplastic therapy (eg, drugs, biologicals, monoclonal antibodies, etc) or radiotherapy within the 3 weeks before enrollment (14 days for regimens with recovery expected within 7 to 14 days). The participant must have recovered (ie, ≤ Grade 1 toxicity or participant's baseline status, except alopecia) from all treatment-related toxicities.
  5. (ECOG) performance status of 0 or 1.
  6. Adequate bone marrow function as defined by:

    • (ANC) ≥ 1,500 cells/mm3 (without need for growth factor support).
    • count ≥ 100,000 cells/mm3 (without need for transfusion or growth factor support).
    • level ≥ 9 g/dL.
  7. Adequate liver function as defined by:

    • \< 1.5 times the (ULN)
    • (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if due to liver )
    • Serum albumin equal to or greater than the lower limit of normal
  8. Adequate renal function as defined by:

    • ≥ 30 mL/minute (can be calculated using serum creatinine value).
  9. No more than 2 previous chemotherapy regimen in the metastatic setting.
  10. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug
    • Adhere to any treatment-specific pregnancy prevention guidelines for paclitaxel

    Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug
    • Adhere to any treatment-specific pregnancy prevention guidelines for paclitaxel.
  11. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  12. Suitable venous access for the study-required blood sampling, including pharmacokinetics (PK).
  13. Ability to swallow tablets.

Exclusion criteria

Exclusion Criteria:

  1. Participants with carcinomatous meningitis.
  2. Participants with symptomatic and/or progressive or treatment with brain edema.
  3. Known to Cremophor® EL, paclitaxel, alisertib or their components.
  4. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting.
  5. Prior history of ≥ Grade 2 neurotoxicity or any toxicity requiring discontinuation from taxane chemotherapy that is not resolved to ≤ Grade 1.
  6. Participants who received prior weekly taxane-based therapy with early disease progression during or within 1 month of completing therapy ( disease).
  7. Any comorbid condition or unresolved toxicity that would preclude administration of weekly paclitaxel.
  8. Systemic treatment with moderate or strong inhibitors must be discontinued at least 14 days before the first dose of alisertib, and the use of these agents is not permitted during the study.
  9. Known gastrointestinal (GI) abnormality (including recurrent nausea or vomiting) or GI procedure that could interfere with or modify the oral intake, absorption, or tolerance of alisertib.
  10. Participants requiring treatment with enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, phenobarbital, oxcarbazepine, primidone, rifampin, rifabutin, rifapentine, or St. John's wort within 14 days before the first dose of alisertib or requiring the use of these medications during the study.
  11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist (premedication for paclitaxel allowed), or pancreatic enzymes. Use of any PPI in either continued or intermittent use will be prohibited during the conduct of the study and participants must discontinue any use of PPI within 4 days before the first dose of alisertib.
  12. Life-threatening or severe central nervous system (CNS), pulmonary, renal, or hepatic disease unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  13. Treatment with any products within 5 half-lives before the first dose of study drug.
  14. Treatment with fully human or chimeric monoclonal antibodies within 42 days before the first dose of study drug (21 days if clear evidence of progression).
  15. Major surgery within 14 days before the first dose of study drug.
  16. Infection requiring systemic intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection.
  17. Known (HIV) positive.
  18. Ongoing or active or infection. Testing is not required in the absence of clinical findings or suspicion.
  19. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of > Grade 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed. Participants with a pacemaker may be enrolled in the study upon discussion with the project clinician.
  20. Female participants who are in the lactation period or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day1 before the first dose of study drug.
  21. Diagnosed with or treated for another within 3 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type may be enrolled in the study if they have undergone complete resection and no evidence of active disease is present.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Dose Escalation Phase)

    Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).

    Drug: Alisertib · Drug: Paclitaxel

  • Experimental
    Cohort 2 (Dose Escalation Phase)

    Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).

    Drug: Alisertib · Drug: Paclitaxel

  • Experimental
    Dose Expansion Cohort

    Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.

    Drug: Alisertib · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From Day 1 to 30 days after the last dose of study drug (approximately 21 months)

  2. Dose Escalation Phase: Number of Participants With Clinically Significant Laboratory Findings

    The number of participants with any markedly abnormal standard safety laboratory values including serum chemistry, hematology, and urine analysis will be collected throughout study. Laboratory values assessed by the investigator to be clinically significant were reported as adverse events.

    Time frame: From Day 1 to 30 days after the last dose of study drug (approximately 21 months)

  3. Dose Escalation Phase: Number of Participants With Clinically Significant Vital Sign Findings

    The number of participants with any markedly abnormal vital sign values (blood pressure, heart rate, and temperature) will be collected throughout study. Vital signs assessed by the investigator to be clinically significant were reported as adverse events.

    Time frame: From Day 1 to 30 days after the last dose of study drug (approximately 21 months)

  4. Dose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  5. Dose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  6. Dose Escalation Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  7. Dose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2 and 3 at multiple time points (up to 12 hours) post-dose

  8. Dose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  9. Dose Escalation Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  10. Dose Escalation Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Tme 0 to Infinity

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  11. Dose Escalation Phase: T½: Terminal Phase Elimination Half-Life of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  12. Dose Expansion Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From Day 1 to 30 days after the last dose of study drug

  13. Dose Expansion Phase: Number of Participants With Clinically Significant Laboratory Findings

    The number of participants with any markedly abnormal standard safety laboratory values will be collected throughout study.

    Time frame: From Day 1 to 30 days after the last dose of study drug

  14. Dose Expansion Phase: Number of Participants With Clinically Significant Vital Sign Findings

    The number of participants with any markedly abnormal vital sign values will be collected throughout study.

    Time frame: From Day 1 to 30 days after the last dose of study drug

  15. Dose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  16. Dose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  17. Dose Expansion Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib

    Time frame: Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

  18. Dose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  19. Dose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  20. Dose Expansion Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  21. Dose Expansion Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

  22. Dose Expansion Phase: T½: Terminal Phase Elimination Half-Life of Paclitaxel

    Time frame: Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

Secondary outcomes

  1. Dose Expansion Phase: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) according to disease response based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Day 21 of every other Cycle beginning with Cycle 2 (Up to 12 months)

07

Results

Posted May 2, 2019

Participant flow

Participants took part in the study at 3 investigative sites in Japan and Republic of Korea from 19 March 2015 to 23 May 2017.

Participant flow — Overall Study
MilestoneCohort 1 (Dose Escalation Phase)Cohort 2 (Dose Escalation Phase)Dose Expansion Cohort
Started900
Completed000
Not completed900
Withdrew: Progressive disease700
Withdrew: Participant received alternative therapy100
Withdrew: Adverse event100

Outcome measures

PrimaryDose Escalation Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From Day 1 to 30 days after the last dose of study drug (approximately 21 months)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1 (Dose Escalation Phase)Cohort 2 (Dose Escalation Phase)
AEs9—
SAEs4—
PrimaryDose Escalation Phase: Number of Participants With Clinically Significant Laboratory Findings

The number of participants with any markedly abnormal standard safety laboratory values including serum chemistry, hematology, and urine analysis will be collected throughout study. Laboratory values assessed by the investigator to be clinically significant were reported as adverse events.

Time frame:
From Day 1 to 30 days after the last dose of study drug (approximately 21 months)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Clinically Significant Laboratory Findings
ParticipantsCohort 1 (Dose Escalation Phase)Cohort 2 (Dose Escalation Phase)
Neutrophil Count Decreased5—
White Blood Cell Count Decreased4—
Blood Antidiuretic Hormone Abnormal1—
PrimaryDose Escalation Phase: Number of Participants With Clinically Significant Vital Sign Findings

The number of participants with any markedly abnormal vital sign values (blood pressure, heart rate, and temperature) will be collected throughout study. Vital signs assessed by the investigator to be clinically significant were reported as adverse events.

Time frame:
From Day 1 to 30 days after the last dose of study drug (approximately 21 months)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsCohort 1 (Dose Escalation Phase)Cohort 2 (Dose Escalation Phase)
Dose Escalation Phase: Number of Participants With Clinically Significant Vital Sign Findings1—
PrimaryDose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2 and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Tme 0 to Infinity
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Escalation Phase: T½: Terminal Phase Elimination Half-Life of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From Day 1 to 30 days after the last dose of study drug

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Number of Participants With Clinically Significant Laboratory Findings

The number of participants with any markedly abnormal standard safety laboratory values will be collected throughout study.

Time frame:
From Day 1 to 30 days after the last dose of study drug

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Number of Participants With Clinically Significant Vital Sign Findings

The number of participants with any markedly abnormal vital sign values will be collected throughout study.

Time frame:
From Day 1 to 30 days after the last dose of study drug

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
Time frame:
Day 1 and Day 3 predose and at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

PrimaryDose Expansion Phase: T½: Terminal Phase Elimination Half-Life of Paclitaxel
Time frame:
Day 1 predose and Day 1, 2, and 3 at multiple time points (up to 12 hours) post-dose

No measurements were reported for this outcome.

SecondaryDose Expansion Phase: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) according to disease response based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Time frame:
Day 21 of every other Cycle beginning with Cycle 2 (Up to 12 months)

No measurements were reported for this outcome.

Adverse events

Collected over First dose of study drug through 30 days after the last dose of any study drug (approximately 21 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (Dose Escalation Phase)1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (Dose Escalation Phase)
DyspnoeaRespiratory, thoracic and mediastinal disorders1/9
PneumothoraxRespiratory, thoracic and mediastinal disorders1/9
DiarrhoeaGastrointestinal disorders1/9
Disease progressionGeneral disorders1/9
PneumoniaInfections and infestations1/9
Small cell lung cancer (disease progression)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/9
DizzinessNervous system disorders1/9
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCohort 1 (Dose Escalation Phase)
DiarrhoeaGastrointestinal disorders5/9
FatigueGeneral disorders5/9
Neutrophil count decreasedInvestigations5/9
StomatitisGastrointestinal disorders4/9
VomitingGastrointestinal disorders4/9
AlopeciaSkin and subcutaneous tissue disorders4/9
White blood cell count decreasedInvestigations4/9
ConstipationGastrointestinal disorders3/9
RashSkin and subcutaneous tissue disorders3/9
HyperglycaemiaMetabolism and nutrition disorders3/9

Baseline characteristics

Safety population is defined as all participants who received at least 1 dose of alisertib. Participants were only enrolled in Dose Escalation Cohort 1.

Age, Continuous
Age, Continuous(years)Cohort 1 (Dose Escalation Phase)
Mean57.48 ± 14.621
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Dose Escalation Phase)
Female2
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Dose Escalation Phase)
Not Hispanic or Latino7
Not reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Dose Escalation Phase)
Asian9
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (Dose Escalation Phase)
Japan3
Korea, Republic Of6
Height
Height(cm)Cohort 1 (Dose Escalation Phase)
Mean162.77 ± 6.907
Weight
Weight(kg)Cohort 1 (Dose Escalation Phase)
Mean63.70 ± 10.165
Body Surface Area
Body Surface Area(m^2)Cohort 1 (Dose Escalation Phase)
Mean1.693 ± 0.1542
08

Study locations

3 sites
  • Chiba, Japan
  • Shizuoka, Japan
  • Seoul, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in May 2017, 26 months.

Results were first posted in May 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2015
First posted
Feb 20, 2015
StartActual
Mar 19, 2015
Primary completionActual
May 23, 2017
CompletionActual
May 23, 2017
Results first posted
May 2, 2019
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02367352
Responsible party
Sponsor
First posted
Feb 20, 2015
Start date
Mar 19, 2015
Primary completion
May 23, 2017
Completion
May 23, 2017
Results posted
May 2, 2019
Last update
Jun 26, 2019

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion